GlassScriptPhysician profile
Lee Pavel
NPI 1831487107
$4,570.09
in general payments reported to CMS, 2019-2025
60 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 79% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,477 · 2022: $710 · 2023: $138 · 2024: $292 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.83 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $318.92 | 2021-2025 | Opdualag, Opdivo |
| Janssen Biotech, INC. | $258.59 | 2021-2025 | Rybrevant, Carvykti |
| Celgene Corporation | $230.09 | 2021-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $228.61 | 2021-2025 | |
| Beone Medicines USA, INC. | $187.81 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $180.76 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Seagen INC. | $180.53 | 2021-2023 | Padcev |
| Array Biopharma INC | $171.72 | 2021-2025 | Braftovi, Tukysa, Mektovi |
| Pharmacyclics LLC, An Abbvie Company | $143.00 | 2021-2022 | |
| Genzyme Corporation | $141.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $120.86 | 2022-2025 | |
| Pulmonx Corporation | $115.60 | 2024 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Amgen INC. | $113.46 | 2021-2022 | |
| Abbott Laboratories | $112.42 | 2024 | Freestyle Libre 3 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Pavel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.